EWING, NJ--(Marketwire - July 15, 2008) - DOR BioPharma, Inc. (OTCBB: DORB) (“DOR” or the “Company”), a late-stage biopharmaceutical company developing products to treat the life-threatening side effects of cancer treatments, serious gastrointestinal diseases and vaccines against certain bioterrorism agents, announced today that it has executed a definitive collaborative agreement with IDIS Limited (“IDIS”), for the supply and distribution within the European Union of the Company’s investigational drug orBec® (oral beclomethasone dipropionate) for the treatment of gastrointestinal Graft-versus-Host disease (“GI GVHD”) via a named patient program (“NPP”).
